Atopic dermatitis, commonly known as eczema, affects a significant portion of the population.
典型的湿疹，也就是我们常说的特应性皮炎，影响了相当一部分人群。
The
atopic personality is characterized by a heightened sensitivity to environmental triggers.
特应性人格的特点是对环境触发因素高度敏感。
My little sister has an
atopic constitution; she easily develops allergies to new foods.
我妹妹体质属于特应性的，对新食物常常会过敏。
Atopic dermatitis can be inherited, but environmental factors also play a crucial role in its development.
特应性皮炎可能有遗传因素，但环境因素在它的形成中也起着关键作用。
The doctor recommended a strict diet for my
atopic child to minimize their skin flare-ups.
医生建议我特应性孩子的饮食要严格控制，以减少皮肤发炎。
Atopic individuals often have a family history of asthma and hay fever.
特应性体质的人往往有哮喘和花粉热的家庭史。
Psychological stress can exacerbate
atopic conditions in some people.
心理压力可能会使一些人的特应性疾病加重。
Environmental pollution seems to increase the prevalence of
atopic disorders in urban areas.
环境污染似乎在城市地区增加了特应性疾病的发生率。
Proper skincare routine is essential for managing the symptoms of
atopic dermatitis.
对于管理特应性皮炎的症状，适当的护肤程序至关重要。
Early intervention and allergen avoidance are key strategies in treating
atopic conditions.
对特应性疾病的早期干预和避免过敏原是治疗的关键策略。
French pharmaceutical company Sanofi announced on Tuesday that Dupixent, the world's first targeted biological agent for atopic dermatitis (AD) treatment, has been approved by China's National Medical Products Administration to treat moderate to severe AD in infants and children aged between six months old and five years old.
法国赛诺菲制药公司周二宣布，世界上第一种治疗特应性皮炎（AD）的靶向生物制剂Dupixent已被中国国家医疗产品管理局批准用于治疗6个月至5岁婴儿和儿童的中重度AD。
Pfizer, the global biopharmaceutical company, held a launch ceremony for Cibinqo – an oral, once-daily highly selective JAK1 (Janus kinase 1) inhibitor, for treating adult patients with moderate-to-severe atopic dermatitis -- in China on Sunday.
周日，全球生物制药公司辉瑞在中国举行了Cibinqo的上市仪式。Cibinqo是一种口服的、每天一次的高选择性JAK1（Janus激酶1）抑制剂，用于治疗中重度特应性皮炎的成年患者。
The launch of this inhibitor marks a globally synchronized R&D and regulatory application process and Pfizer's second breakthrough in Atopic dermatitis (AD) treatment.
该抑制剂的推出标志着全球同步的研发和监管应用程序，以及辉瑞在特应性皮炎（AD）治疗方面的第二次突破。
By further enriching the AD portfolio, Pfizer is set to meet the full range of treatment needs for AD patients with mild, moderate and severe atopic dermatitis.
通过进一步丰富AD产品组合，辉瑞将满足轻度、中度和重度特应性皮炎AD患者的全方位治疗需求。
Atopic dermatitis is a common chronic skin disease characterized by intense itching, skin inflammation and skin barrier defects.
特应性皮炎是一种常见的慢性皮肤病，以强烈瘙痒、皮肤炎症和皮肤屏障缺陷为特征。
According to Reed, Sanofi has prioritized multiple potentially transformative therapies in areas of high unmet patient need, including Dupixent, the world's first targeted biological agent that has been approved for treating moderate-to-severe atopic dermatitis, Fitusiran and Efanesoctocog alfa (BIVV001) for treatment of hemophilia, Amlitelimab for treatment of inflammatory disorders, Amcenestrant for treatment of breast cancer, RSV Vaccine Nirsevimab, and Tolebrutinib for treatment of multiple sclerosis.
据Reed介绍，赛诺菲已将多种潜在的变革性疗法优先用于患者需求未得到高度满足的领域，包括世界上第一种被批准用于治疗中重度特应性皮炎的靶向生物制剂Dupixent，用于治疗血友病的Fitusiran和Efanesoctocog alfa（BIVV001），用于治疗炎症性疾病的Amlitelimab，Amcenestant治疗乳腺癌症，RSV疫苗Nirsevimab和Tolebrutinib治疗多发性硬化症。
Dupixent, the world's first targeted biological agent for atopic dermatitis treatment by Sanofi, is also being showcased at the French company's booth again this year.
赛诺菲公司全球首款治疗特应性皮炎的靶向生物制剂Dupixent今年也将再次在这家法国公司的展台上展出。
In the recent years, through constant exploration, we have established an increasingly complete pipeline of innovative drugs in the inflammation and immunity field, covering diseases such as RA, ankylosing spondylitis, atopic dermatitis, and alopecia areata.
近年来，通过持续探索，我们在炎症与免疫领域建立起日趋完善的创新药物管线，覆盖了包括类风湿关节炎、强直性脊柱炎、特应性皮炎和斑秃等疾病。
Some products that have not entered the China market or are still in the research and development phase, including a liquid botulinum toxin and a medical therapy to treat atopic dermatitis, will also be exhibited.
一些尚未进入中国市场、甚至还在研发中的产品，包括液体肉毒杆菌毒素和治疗特应性皮炎的疗法，也都会在进博会上亮相。
An innovative targeted biological agent developed by French pharmaceutical company Sanofi was recently approved by the National Medical Products Administration to treat moderate to severe atopic dermatitis in teenagers aged 12 and above.
近日，法国制药公司赛诺菲(Sanofi)开发的一种创新性靶向生物制剂已获得国家药品监督管理局(NMPA)的批准，用于治疗12岁及以上青少年的中重度特应性皮炎。
For example, there will be a cooperation memorandum signing regarding the ecosystem for atopic dermatitis (AD), a common immunoinflammatory disease that seriously affects the health and living quality of millions of sufferers in the country.
例如，将会有关于异位性皮炎（AD）生态系统合作备忘录的签署。异位性皮炎是一种常见的免疫炎症性疾病，严重影响了国内数百万患者的身体健康和生活质量。
The world's first, and so far, the only targeted biological agent approved in the United States and Europe to treat atopic dermatitis among adult patients also made its China debut during the CIIE.
Atopic dermatitis, which is more often referred to as eczema, is characterized by chronic and recurrent itching and skin injury.
One patient suffering from severe atopic dermatitis became the first recipient, whose condition was improved and quality of life was elevated.
"Six rare-disease drugs and new vaccines from the company made their debut at the expo, including Dupixent, the first and only targeted biological agent approved in the US and European Union for the treatment of moderate to severe atopic dermatitis in adults.
Dupixent is the first and only targeted biological agent approved for the treatment of atopic dermatitis, a common immunoinflammatory disease characterized by chronic itching and skin injuries, and covers all age groups.
Ma Lin of Beijing Children's Hospital said 40 percent to 50 percent of infants with CMPA also suffer from atopic dermatitis, and according to a 2015 survey by the Children's Group of the Chinese Society of Dermatology and Skin Diseases Branch, the incidence has increased significantly year-on-year.
未经许可，严禁转发。QQ交流群：688169419